November 27, 2023, Alex Berenson

Researchers for American pharmaceutical giant Moderna have allegedly halted early-stage clinical trials for its mRNA Epstein-Barr virus vaccine following concerns that an adolescent who participated developed a case of myocarditis, according to a report published by researcher Alex Berenson. 

Around 150 adolescents and 270 people aged between 18 and 30 have been participating in the vaccine Phase 1 trial, aiming to eradicate the Epstein-Barr virus, which causes mononucleosis.

Berenson published details he says are from an internal company email states, “We [Moderna] have been informed today of an adolescent subject enrolled in Part B of the protocol that has met a pause of ‘possible case of myocarditis.’ In line with protocol guidance, this necessitates immediate suspension of all dosing for ALL adolescent subjects.” 

“We do not yet know exactly when dosing may resume,” the email adds. 

The pharmaceutical company has not publicly commented on the claimed trial pause. The internal email was provided to “Unreported Truths” anonymously by someone “not employed by Moderna.” 

Potential adverse effects of mRNA vaccines are not merely limited to myocarditis, however, as the COVID-19 vaccines have been similarly linked to health problems including “menstrual disturbance,” “Tinnitus,” and seizures in children.